Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background Obsessive–compulsive disorder (OCD) is clinically heterogeneous. Previous studies have reported different patterns of treatment response to serotonin reuptake inhibitors (SRI) based on symptom dimension. Our objective was to replicate these results in OCD patients who participated in one of four randomized, placebo-controlled, clinical trials (RCT). Methods A total of 165 adult OCD subjects participated in one or more eight-week RCT with clomipramine, fluvoxamine, or fluoxetine. All subjects were classified as having major or minor symptoms in four specific OC symptom dimensions that were derived in a previous factor analytic study involving many of these same patients. Ordinal logistic regression was used to test the association between OC symptom dimensions and SRI response. Results We found a significant association between the symptom dimension involving sexual, religious and harm-related obsessions as well as checking compulsions (AGG/SR) and improved SRI response. This increased rate of SRI response was experienced primarily by individuals with harm-related obsessions. Over 60% of patients with AGG/SR OCD symptoms were rated as very much improved after SRI treatment. Limitations As some of the RCTs included were conducted prior to the development of the Yale-Brown Obsessive–compulsive Scale (Y–BOCS), improvement in OCD severity was assessed using the Clinical Global Improvement (CGI) Scale. Data from the double-blind and open-label continuation phases of these trials was collapsed together to increase statistical power. Conclusions Patients with OCD vary in their response to SRIs. The presence of AGG/SR symptoms is associated with an initial positive response to SRIs. These data add to the growing body of work linking central serotonin systems with aggressive behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Obsessive-Compulsive Inventory: Development and validation of a short version.
Foa, E. B., Huppert, J. D., Leiberg, S., Langner, R., Kichic, R., Hajcak, G., & Salkovskis, P. M. (2002) · Psychological Assessment · doi:10.1037/1040-3590.14.4.485 · Cited by 2,959
A multidimensional model of obsessive-compulsive disorder
Mataix-Cols, D., do Rosario-Campos, M. C., & Leckman, J. F. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.228 · Cited by 1,074
Self-citationSymptoms of obsessive-compulsive disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.7.911 · Cited by 766
Self-citationMataix-Cols, D., Rauch, S. L., Manzo, P. A., Jenike, M. A., & Baer, L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1409 · Cited by 716 · cited 7×
“Specifically, HRD symptoms also have been reported to be associated with poor Serotonin Reuptake Inhibitor (SRI) response in most (Mataix-Cols et al., 1999; Samuels et al., 2002; Stein et al., 2007) but not all studies (Saxena et al., 2007).”
InfluentialMeta-analysis of the symptom structure of obsessive–compulsive disorder
Bloch, M. H., Landeros-Weisenberger, A., Rosario, M. C., Pittenger, C., & Leckman, J. F. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020320 · Cited by 681
Self-citationSelective Alteration of Personality and Social Behavior by Serotonergic Intervention
Knutson, B., Wolkowitz, O. M., Cole, S. W., Chan, T., Moore, E. A., Johnson, R. C., Terpstra, J., Turner, R. A., & Reus, V. I. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.3.373 · Cited by 500
Item-by-Item Factor Analysis of the Yale-Brown Obsessive Compulsive Scale Symptom Checklist
Feinstein, S. B., Fallon, B. A., Petkova, E., & Liebowitz, M. R. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.2.187 · Cited by 122
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“dopamine system and aggressive behaviors by the serotonin system [810,812].”
BackgroundObsessive-compulsive disorder: An integrative genetic and neurobiological perspective
Pauls, D. L., Abramovitch, A., Rauch, S. L., & Geller, D. A. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3746 · Cited by 793
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“…et al., 2008a; Katerberg et al., 2009; Pinto et al., 2009); it has been suggested that symptomatic subtypes may correspond to discrete patterns of abnormal brain activation (Mataix-Cols et al., 2004; van den Heuvel et al., 2009) and treatment response (e.g. Landeros-Weisenberger et al., 2010).”
BackgroundSelf-citationLeckman, J. F., Denys, D., Simpson, H. B., Mataix-Cols, D., Hollander, E., Saxena, S., Miguel, E. C., Rauch, S. L., Goodman, W. K., Phillips, K. A., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20669 · Cited by 411
“For example, Landeros-Weisenberger et al.([181]) evaluated the results from a total of 165 adult OCD subjects who participated in one or more 8-week randomized controlled clinical trials with clomipramine, fluvoxamine, or fluoxetine.”
ResultSelf-citationEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Gowda, S. M., Narayanaswamy, J. C., Hazari, N., Bose, A., Chhabra, H., Balachander, S., Bhaskarapillai, B., Shivakumar, V., Venkatasubramanian, G., & Reddy, Y. C. J. (2019) · Brain Stimulation · doi:10.1016/j.brs.2019.02.005 · Cited by 96
Fradkin, I., Adams, R. A., Parr, T., Roiser, J. P., & Huppert, J. D. (2020) · Psychological Review · doi:10.1037/rev0000188 · Cited by 89
Bloch, M. H., Green, C., Kichuk, S. A., Dombrowski, P. A., Wasylink, S., Billingslea, E., Landeros-Weisenberger, A., Kelmendi, B., Goodman, W. K., Leckman, J. F., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22103 · Cited by 94
“However, this finding was likely the result of confounding because these symptoms were highly correlated with initial treatment response previously in this same sample.[20] We found no correlation with other clinical factors such as OCD symptom dimensions, baseline levels of comorbid psychiatric illnesses, the age of…”
ResultSelf-citationThe clinical utility of symptom dimensions in obsessive–compulsive disorder
Matsunaga, H., Hayashida, K., Kiriike, N., Maebayashi, K., & Stein, D. J. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.09.005 · Cited by 58
Bragdon, L. B., Gibb, B. E., & Coles, M. E. (2018) · Depression and Anxiety · doi:10.1002/da.22785 · Cited by 57
“In addition to showing unique associations with different core motivations (Ecker & Gönner, 2008), they have shown to be related to differential patterns of comorbidity, age of onset, and treatment response (Coles, Pinto, Mancebo, Rasmussen,&Eisen, 2008;Hasler et al., 2005; Jenike, Baer,Minichiello, Rauch, & Buttolph,…”
BackgroundRück, C., Larsson, K. J., & Mataix-Cols, D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.11.003 · Cited by 32
“, 2005) and its response to conventional treatments (Alonso et al., 2001; Landeros-Weisenberger et al., 2010; Mataix-Cols et al., 1999; Rufer et al., 2006; Stein et al., 2007, 2008).”
BackgroundMethodVan Schalkwyk, G. I., Bhalla, I. P., Griepp, M., Kelmendi, B., Davidson, L., & Pittenger, C. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415579919 · Cited by 29
Self-citation
Metadata
- Authors
- Landeros-Weisenberger, A., Bloch, M. H., Kelmendi, B., Wegner, R., Nudel, J., Dombrowski, P., Pittenger, C., Krystal, J. H., Goodman, W. K., & Leckman, J. F.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 121
- Issue
- 1-2
- Pages
- 175-179
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2128162570
- Cited by
- 103
- References
- 7
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.